Eli Lilly’s stock plunges as investors eye obesity-drug competition

Eli Lilly & Co.’s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers.

Previous post ‘Inflationary’ tariffs by U.S. could upset expectations for multiple Fed rate cuts into 2025
Next post Small-cap stock surge doesn’t mean sell the S&P 500 — but it’s going that way